Research

Our paper of the month for October investigates vestibular function in patients with dizziness, vertigo and postural symptoms following COVID-19 vaccination.

The 2017 McDonald criteria showed higher sensitivity, lower specificity, and similar accuracy in predicting clinically definite multiple sclerosis compared to 2010 McDonald criteria, while shortening time to its diagnosis.

Insidious disability accrual starts already in the earliest phases of multiple sclerosis and becomes dominant over the disease course, suggesting an ongoing process of inflammation and/or degeneration secondary to disease burden.

Epstein-Barr virus infection is the strongest known risk factor for the development of multiple sclerosis, and it precedes preclinical manifestation of the disease suggesting a possible causal role

In multiple sclerosis, an impairment of the glymphatic system may contribute to pathology accrual in the central nervous system and disability progression.

Baseline characteristics of Aβ-positive individuals can help identify those who will remain tau-negative for at least 5 years.

Greater diffusion restriction in the white matter of amyloid-beta-positive cognitively unimpaired individuals supports the role of inflammation in early preclinical AD.

New Neurology Update from Stroke Scientific Panel

The revised Boston criteria allow for a more accurate diagnosis of cerebral amyloid angiopathy

WGS can reliably assess the most common neurological disease-causing repeat expansions, further supporting its implementation in clinical practice.

New Neurology Update from Palliative Care is in! Read more about the topics here

The EAN Guideline Production Group has developed a template for EAN guideline protocols, to facilitate production of high quality guidelines.

This month we have selected two phase-2 trials investigating α-synuclein-binding antibodies as potential disease-modifying treatment of Parkinson’s disease.

Our authors of the month for September conclude that people with Parkinson's Disease and parkinsonism showed a higher risk of SARS-CoV-2 infection throughout the first 15 months of the pandemic.

Our research paper of the month presents the results of the ‘SWIFT direct’ trial, a randomised, open-label, blinded-outcome trial, aiming to investigate whether thrombectomy alone would be non-inferior to thrombectomy plus intravenous alteplase in patients with acute ischaemic stroke due to anterior circulation large vessel occlusion.